Investors & Media

Ionis announces positive data from GSK’s Phase 2b clinical study of bepirovirsen

GSK plans to advance bepirovirsen into Phase 3 development program in 1H 2023 CARLSBAD, Calif. , Nov. 8, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBV

Read more
You are now leaving to visit